Industry News

FDA approves weight-management drug Contrave

Centerwatch - Fri, 2014-09-12 08:49
The FDA has approved Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
Categories: Industry News

MsFLASH-04: Pilot Trial: Telephone Behavioral Therapy for Menopause-related Sleep Disturbance

sleep - Thu, 2014-09-11 20:00
Status: Recruiting, Condition Summary: Hot Flashes; Menopause; Vasomotor Disturbance; Sleep
Categories: Industry News

Almac selected as a national champion in the 2014/15 European Business Awards

Centerwatch - Thu, 2014-09-11 11:43
Almac, a contract development and manufacturing organization, has been named national champion in the UKTI Award for Innovation category in this year’s European Business Awards—a competition supported by businesses leaders, academics, media and political representatives across Europe. 
Categories: Industry News

Louis J. DeGennaro named president and CEO of the Leukemia & Lymphoma Society

Centerwatch - Thu, 2014-09-11 11:33
The Leukemia & Lymphoma Society (LLS) has appointed Louis J. DeGennaro, Ph.D., president and CEO, effective immediately.
Categories: Industry News

SRI International, Nobelpharma partner on endometriosis treatment

Centerwatch - Thu, 2014-09-11 09:41
SRI International, a California-based independent nonprofit research institute, and Nobelpharma, a Japanese pharmaceutical company, have entered into a licensing agreement to test SR16234, an SRI drug candidate that may be effective in treating endometriosis. SR16234 is a member of a class of drugs known as selective estrogen receptor modulators (SERMs) that regulate the effects of the hormone estrogen.
Categories: Industry News

Medidata, Icon partner to bring efficiencies to ePRO

Centerwatch - Thu, 2014-09-11 09:40
Medidata, a NewYork-based global provider of cloud-based solutions for clinical research in life sciences, and global CRO Icon have formed a joint initiative designed to bring new efficiencies to the administration of electronic patient-reported outcomes (ePROs) in clinical trials. The new offering provides sponsors with an ePRO solution that reduces costs, saves time and enhances patient engagement.
Categories: Industry News

MabVax Therapeutics, MSKCC and Juno Therapeutics ink agreement

Centerwatch - Thu, 2014-09-11 09:38
MabVax Therapeutics Holdings, a San Diego-based clinical stage oncology drug development company, has entered into agreements with New York City’s Memorial Sloan-Kettering Cancer Center (MSKCC) and Seattle-based Juno Therapeutics for the development of novel therapeutic products using antibody targeting sequences derived from the fully-human antibodies discovered using the company's internally developed antibody discovery platform.
Categories: Industry News

PharmAthene awarded $28.1M to develop thermostable anthrax vaccine

Centerwatch - Thu, 2014-09-11 09:36
PharmAthene, an Annapolis, Md.-based biodefense company developing medical countermeasures against biological and chemical threats, has announced the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, has awarded the company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next-generation anthrax vaccine based on the company's proprietary rPA anthrax vaccine technology platform.
Categories: Industry News

NICE to seek greater access to clinical trial data when appraising drugs

Centerwatch - Thu, 2014-09-11 09:32
NICE will ask for access to clinical trial data from European regulatory authorities if pharmaceutical companies fail to supply all relevant data. The move follows calls for increasing transparency from pharma companies and comes after Roche was criticized for its handling of data for the pandemic flu drug Tamiflu.
Categories: Industry News

Report: Psoriatic arthritis market will reach more than $3.5B in 2023

Centerwatch - Thu, 2014-09-11 09:28
The market for psoriatic arthritis (PsA) therapies will grow nearly 66%, increasing to $3.7 billion in 2023, due to the continued uptake of premium-price biologics and novel therapies expected to launch during the 2013 to 2023 forecast period, according to Burlington, Mass.-based Decision Resources Group.
Categories: Industry News

Seattle Genetics, Genmab enter into antibody-drug conjugate collaboration

Centerwatch - Thu, 2014-09-11 09:20
Seattle Genetics, a biotech company focused on development and commercialization of innovative antibody-based therapies for cancer, and Genmab, a Denmark-based international biotech company specializing in differentiated human antibody therapeutics for cancer, have entered into an additional antibody-drug conjugate (ADC) collaboration.
Categories: Industry News

18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease

Alzheimers - Wed, 2014-09-10 20:00
Status: Recruiting, Condition Summary: Alzheimer's Disease
Categories: Industry News

Additions/Deletions for Prescription and OTC Drug Product Lists

FDA News - Wed, 2014-09-10 15:28
The list has been updated through August 2014.
Categories: Industry News

PMG Research forms its 11th clinical site

Centerwatch - Wed, 2014-09-10 11:07
PMG Research (PMG), an integrated network of clinical research facilities in the southeastern U.S., has established its 11th clinical research site, PMG Research of Rocky Mount. PMG Research has assumed ownership and operation of the clinical research department at Boice-Willis Clinic in Rocky Mount, N.C., further expanding PMG’s presence in eastern North Carolina. This new site enhances PMG’s access to an additional 130,000 patients.
Categories: Industry News

Survey reveals knowledge gaps among Parkinson's patients and caregivers

Centerwatch - Wed, 2014-09-10 11:04
Information and specialized care can help patients become more engaged in their own treatment and in the Parkinson's disease (PD) community, according to a recent online survey of more than 1,500 PD patients, caregivers and physicians conducted by Harris Poll on behalf of the Michael J. Fox Foundation and AbbVie.
Categories: Industry News

Report: clinical trials will continue to play a key role in oncology device market

Centerwatch - Wed, 2014-09-10 11:03
The U.S. interventional oncology device market will see strong growth, reaching a value of $760 million by 2023, according to Decision Resources Group. Rising cancer incidence rates, combined with the ineffectiveness of chemotherapy and demand for less invasive procedures, will support interventional oncology device uptake.
Categories: Industry News

Almac’s releases clinical supply chain management service

Centerwatch - Wed, 2014-09-10 11:02
Almac, a contract development and manufacturing organization headquartered in Craigavon, Northern Ireland, has released a new clinical Supply Chain Management (SCM) service as a response to growth in demand for biologics and global trials.
Categories: Industry News

NeuroVive Pharmaceutical, Oncore Biopharma ink $150M agreement

Centerwatch - Wed, 2014-09-10 11:01
NeuroVive Pharmaceutical, a Swedish mitochondrial medicine company, has signed an exclusive global out-licensing agreement with the Pennsylvania-based OnCore BioPharma for the development and commercialization of NeuroVive’s drug candidate NVP018 for oral treatment of chronic hepatitis B virus (HBV) infection. The agreement could give NeuroVive a total of $150 million in conditional milestone payments, plus royalties on future drug sales.
Categories: Industry News

Livongo Health launched

Centerwatch - Wed, 2014-09-10 11:00
Livongo Health, a California-based consumer digital health company, has launched with a vision to empower people with chronic conditions to live better through the combined power of technology, real-time personalized information and support from a chosen care team.
Categories: Industry News
Syndicate content